Capricor Suit Filed, UWM Class Action Deadline Set
Capricor Suit Filed, UWM Class Action Deadline Set
Anonymous
Key Points
1
Faruqi & Faruqi is inviting investors who purchased or acquired Capricor securities during the alleged class period to discuss their legal options directly with partner Josh Wilson, providing telephone numbers 877-247-4292 and 212-983-9330, extension 1310.
2
Levi & Korsinsky says investors may explore a potential recovery even if they still hold their Capricor shares, and states that participation carries no cost or obligation.
3
The firms describe slightly different endpoints for the alleged class period: Faruqi & Faruqi identifies July 26, 2026, while Levi & Korsinsky identifies July 29, 2026, as the end date for potentially affected purchases.
Multiple law firms have filed securities class actions against Capricor Therapeutics, alleging the company and its executives misled investors about regulatory risks for Deramiocel, an experimental treatment for Duchenne muscular dystrophy. Faruqi & Faruqi and Levi & Korsinsky claim Capricor changed its statistical analysis plan for clinical data without securing FDA approval before resubmitting the treatment's application, creating a risk of rejection. Investors who purchased Capricor securities from December 17, 2025 through late July 2026 may be affected.
The deadline to seek lead-plaintiff status in the class action is September 28, 2026, according to multiple law firm notices. Faruqi & Faruqi identifies July 26, 2026 as the class period end date, while Levi & Korsinsky cites July 29, 2026. Investors can pursue recovery even if they still hold Capricor shares, with no upfront cost or obligation to participate.
What Capricor Is Accused Of Doing
Capricor allegedly changed its statistical analysis plan for Deramiocel clinical trial data without first getting FDA agreement. The company then resubmitted its application for regulatory approval. Faruqi & Faruqi claims this move created substantial risk that the FDA would find insufficient evidence the drug works and reject approval outright. The lawsuits say executives failed to disclose these regulatory dangers to shareholders before the stock price dropped.
Affected Investors and Class Action Window
The alleged class period runs from December 17, 2025 through late July 2026, though the exact end date varies slightly between law firms. Faruqi & Faruqi partner Josh Wilson is accepting calls at 877-247-4292 and 212-983-9330, extension 1310, to discuss legal options with affected investors. Levi & Korsinsky emphasizes that investors can explore recovery even if they currently hold Capricor shares and face zero cost or obligation upfront.
Multiple Firms Competing for Lead Plaintiff Role
At least five law firms—Faruqi & Faruqi, Levi & Korsinsky, Kahn Swick & Foti, Bernstein Liebhard, and Kaplan Fox & Kilsheimer—have announced separate cases and are soliciting investors ahead of the September 28, 2026 lead-plaintiff deadline. Each firm is urging investors to contact them directly. This competitive filing environment is typical in securities class actions, where multiple counsel may seek to become lead counsel for the class.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
29
Reach
45
A
AnonymousAuthor
